Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study

Table 4 Association between the neprilysin level with all-cause death and major adverse cardiovascular events

Model	HR (95% CI)	P value
All-cause death
Model 1 (univariate)	1.437 (0.810–2.552)	0.215
Model 2 (age, sex)	1.567 (0.882–2.783)	0.125
Model 3 (age, sex, smoking)	1.575 (0.887–2.798)	0.121
Model 4 (age, sex, LVEF)	1.598 (0.898–2.842)	0.111
Model 5 (age, sex. NT-proBNP)	1.414 (0.789–2.534)	0.244
Model 6^a	1.701 (0.892–3.247)	0.107
Major adverse cardiovascular events.
Model 1 (univariate)	1.307 (0.716–2.386)	0.384
Model 2 (age, sex)	1.431 (0.783–2.614)	0.244
Model 3 (age, sex, smoking)	1.431 (0.784–2.613)	0.244
Model 4 (age, sex, LVEF)	1.528 (0.834–2.798)	0.170
Model 5 (age, sex. NT-proBNP)	1.309 (0.705–2.430)	0.394
Model 6^a	1.624 (0.843–3.127)	0.147

HR indicates hazard ratio, CI confidence interval, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-B type natriuretic peptide
^aAfter adjustment for age, sex, body mass index, hypertension, diabetes mellitus, dyslipidemia, smoking, family history of coronary artery disease, prior stroke, clinical presentation (myocardial infarction vs. angina), LVEF, NT-proBNP, and estimated glomerular filtration rate

ISSN: 1471-2261